4 active not recruiting, 2 completed, 2 recruiting, 2 terminated. 7 Phase 2, 6 Phase 1, 2 Phase 3.
Follow Unresectable Head and Neck Squamous Cell Carcinoma: new trials by email Literature Review of Unresectable Head and Neck Squamous Cell Carcinoma trials Research Report on Unresectable Head and Neck Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-09-03 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy - Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | Phase 3 | Terminated | PDS Biotechnology Corp. | 12 | 2025-05-30 | 2026-09-02 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Biospecimen Collection, Computed Tomography, Elimusertib - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 7 | 2022-07-06 | 2026-08-21 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer Hafnium Oxide-containing Nanoparticles NBTXR3, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy - Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-03-09 | 2023-09-13 | |
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 BNT113, Pembrolizumab - Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer | Phase 2 / Phase 3 | Active not recruiting | BioNTech SE | 358 | 2021-01-07 | 2026-10-14 |
| Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration - Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 3 | 2020-10-19 | 2024-10-29 |
| Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat ImmunoPulse, Epacadostat, Pembrolizumab - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | Chase Heaton, MD | 14 | 2019-05-02 | 2023-05-09 |
| Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Cabozantinib, Pembrolizumab - Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Emory University | 36 | 2018-09-18 | 2026-01-23 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab - Lymphoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | Rutgers, The State University of New Jersey | 14 | 2017-10-03 | 2023-12-06 |
| Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery Cetuximab, Edodekin alfa, Laboratory Biomarker Analysis - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 23 | 2011-10-26 | 2026-07-29 |
Squamous Cell Carcinoma of Head and Neck (11) · Neoplasm Metastasis (4) · Carcinoma (3) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Hypopharyngeal Neoplasms (3) · Laryngeal Neoplasms (3) · Melanoma (3) · Carcinoma, Merkel Cell (2) · Carcinoma, Transitional Cell (2) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Mouth Neoplasms (2) · Oropharyngeal Neoplasms (2) · Uterine Cervical Neoplasms (2)
Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms by Site (12) · Neoplasms, Glandular and Epithelial (12) · Carcinoma, Squamous Cell (11) · Head and Neck Neoplasms (10) · Carcinoma (9) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Adenocarcinoma (3) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3)
pembrolizumab (8) · Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · Radiosurgery (3) · Nivolumab (2) · (225)Ac-DOTA-c(RGDyK) (1) · BAY 1895344 (1) · Biopsy (1) · Cetuximab (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Electroporation (1) · Electroporation Therapies (1) · Immunoglobulin G (1) · Interleukin-12 (1)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · BioNTech SE (1) · Chase Heaton, MD (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1) · PDS Biotechnology Corp. (1) · Rutgers, The State University of New Jersey (1)
United States (10) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Mexico (1)
Yvonne M Mowery (2) · Biren Saraiya (1) · Chase Heaton, MD (1) · Clifton D Fuller (1) · Jack Phan, MD (1) · Kirk V Shepard, MD (1) · Nabil F. Saba, MD (1) · Shailender Bhatia, MD (1) · William E Carson (1) · Yanyan Lou, MD, PhD (1)
PMID 34841093, PMID 35780243, PMID 37012550, PMID 39462179
UM1CA186690 (2), N01CM00070 (1), P30CA016058 (1), P30CA072720 (1), P30CA138292 (1), U01CA076576 (1), UM1CA186712 (1)